谁藏起来了教案:求助医学或生物学翻译

A different therapeutic strategy targeting VEGF and its receptors could be based on active immunotherapy: a “cancer vaccine” approach. Recent experiments with mouse tumor models suggest that immunization with VEGF and VEGF receptors can indeed lead to anti-tumor effects. It is noteworthy however that these efforts have not centered on a combined anti-ligand/anti-receptor approach, nor in the quest for eliciting a simultaneous response based on neutralizing antibodies and CTLs, as the CIGB proposes now (see below). In the specific case of VEGF peptides or whole molecule, authors have directed immunization to specifically produce (in an “Avastin-like” strategy) a strong anti-VEGF neutralizing antibody response, or have found that experimental anti-tumor effects mainly rely on the production of a CD4+ dependent humoral response, after naked DNA vaccination with xenogeneic VEGF. In the case of the VEGF receptor, the studies of other groups using all or some of the extracellular domains of mVEGFR-2 in transfected dendritic cells, as a DNA vaccine delivered by attenuated Salmonella typhimurium or as a naked DNA vaccine have evidenced that it is possible to break peripheral T-cell tolerance against the murine molecule. In fact, CTLs and not antibodies have been the main anti-tumor effecter mechanism in these other cases.